Goldman Sachs Starts Human Genome Sciences (HGSI) at Neutral, Sees Slower Benlysta Launch
Tweet
Share
E-mailGet Alerts HGSI Hot Sheet
Price: $14.24 --0%
Rating Summary:
3 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Goldman Sachs initiates coverage on Human Genome Sciences (NASDAQ: HGSI) with a Neutral and $25 price target.
The firm expects FDA approval of Benlysta by March 10, but see a slower launch than the Street. The firm cited "mild" efficacy of the drug, concerns of a narrower label, and the lack of definitive efficacy data in African Americans.
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $25.34 yesterday.
The firm expects FDA approval of Benlysta by March 10, but see a slower launch than the Street. The firm cited "mild" efficacy of the drug, concerns of a narrower label, and the lack of definitive efficacy data in African Americans.
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $25.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- Keefe, Bruyette & Woods Resumes Bank of Montreal (BMO:CN) (BMO) at Outperform
- DA Davidson Starts Comfort Systems USA (FIX) at Buy
Create E-mail Alert Related Categories
Insiders' Blog, New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
